EARLY RESULTS FROM THE EFFECTIVENESS AND SAFETY EVALUATION OF BIOSIMILAR RITUXIMAB AND BRAND-RITUXIMAB IN GLOMERULAR INFLAMMATORY DISEASE (submitted in 2019)